We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

17 hedge funds and large institutions have $7.6M invested in Summit Therapeutics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.42% less ownership

Funds ownership: 5.63% → 4.21% (-1.4%)

15% less funds holding

Funds holding: 20 → 17 (-3)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

86% less capital invested

Capital invested by funds: $53.3M → $7.6M (-$45.7M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $45K

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
5
Closed
7
Calls
–
Puts
$45K
Net Calls
-$45K
Net Calls Change
-$45K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$363K
2
VF
Virtu Financial
New York
+$231K
3
RJFSA
Raymond James Financial Services Advisors
Florida
+$192K
4
FFW
Fusion Family Wealth
New York
+$128K
5
Simplex Trading
Simplex Trading
Illinois
+$97.6K

Top Sellers

1
Axa
Axa
France
-$4.36M
2
GPCM
Granite Point Capital Management
Massachusetts
-$1.81M
3
HCM
Highbridge Capital Management
New York
-$1.03M
4
Renaissance Technologies
Renaissance Technologies
New York
-$714K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$639K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPU
1
Lansdowne Partners (UK)
United Kingdom
$3.91M – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$1.78M -$298K -23,280 -3%
Morgan Stanley
3
Morgan Stanley
New York
$559K -$11.7K -910 -0.4%
First Eagle Investment Management
4
First Eagle Investment Management
New York
$478K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$269K -$714K -55,800 -34%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$261K -$389K -30,417 -22%
Millennium Management
7
Millennium Management
New York
$126K +$363K +28,371 +122%
Deutsche Bank
8
Deutsche Bank
Germany
$57K -$467K -36,437 -61%
VF
9
Virtu Financial
New York
$44K +$231K +18,027 New
RJFSA
10
Raymond James Financial Services Advisors
Florida
$37K +$192K +15,000 New
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$29K – – –
FFW
12
Fusion Family Wealth
New York
$25K +$128K +10,000 New
Simplex Trading
13
Simplex Trading
Illinois
$18K +$97.6K +7,619 New
SWM
14
SeaCrest Wealth Management
New York
$1K +$2.05K +160 +99%
PC
15
Polar Capital
United Kingdom
$858 – – –
Axa
16
Axa
France
– -$4.36M -338,000 Closed
GPCM
17
Granite Point Capital Management
Massachusetts
– -$1.81M -150,000 Closed
HCM
18
Highbridge Capital Management
New York
– -$1.03M -80,000 Closed
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
– -$639K -49,553 Closed
JP Morgan Chase
20
JP Morgan Chase
New York
– -$84K -6,511 Closed
TRCT
21
Tower Research Capital (TRC)
New York
– -$6K -472 Closed
Bank of Montreal
22
Bank of Montreal
Ontario, Canada
– -$3K -260 Closed
Bank of America
23
Bank of America
North Carolina
– +$896 +70 +233%

SMMT Hedge Fund Activity: Q2 2018 in Review

17 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2018, worth a combined $7.6M — down 86% from $53.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SMMT and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Millennium Management, adding an estimated $363K. The largest seller was Axa, exiting entirely with an estimated $4.36M sold.

  • 17 institutional investors held Summit Therapeutics (SMMT) as of Q2 2018, down from 20 in Q1 2018.
  • Funds reported $7.6M of Summit Therapeutics stock for Q2 2018, down 86% quarter-over-quarter.
  • 4 funds opened new Summit Therapeutics positions in Q2 2018 and 7 closed out, a net change of -3 holders.
  • The largest Summit Therapeutics buyer in Q2 2018 was Millennium Management, an estimated $363K added.
  • The largest Summit Therapeutics seller in Q2 2018 was Axa, an estimated $4.36M sold.

Based on aggregated 13F filings for Q2 2018.